Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261)

Gerald H. Friedland, Richard B Pollard, Brigitte Griffith, Michael Hughes, Gene Morse, Roland Bassett, William Freimuth, Lisa Demeter, Elizabeth Connick, Thomas Nevin, Martin Hirsch, Margaret Fischl

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

To evaluate the antiretroviral activity of delavirdine mesylate, a nonnucleoside reverse transcriptase inhibitor of HIV-1, we performed a phase II, randomized, double-blind, multicenter trial comparing the three-drug combination of delavirdine with zidovudine and didanosine to two-drug combinations of these drugs. Patients with CD4 cell counts between 100 and 500 cells/mm3 without prior or <6 months of monotherapy with zidovudine or didanosine were randomized to one of four arms and observed on a follow-up basis for 48 weeks. In total, 544 patients were evaluated. In those assigned to the three-drug regimen, mean short-term (weeks 4-12) and long-term (weeks 40-48) change in CD4 cells from baseline were 49.3 ± 8.1 and 65.4 ± 13.4 cells/mm3, respectively; mean short-term and long-term HIV-1 RNA changes from baseline were -1.13 log10 ± 0.12 and -0.73 ± 0.12 copies/ml, respectively. These responses in CD4 cell counts and HIV-1 RNA levels were better in comparisons with each of the two-drug arms at all study points; however, differences were not consistently significant. Gastrointestinal side effects were experienced by 33% of patients (178 of 544), and 30% (121 of 407) receiving delavirdine experienced rash, only one case of which was severe. In this study, therapy with delavirdine + zidovudine + didanosine was safe and showed modest, but not always significant, antiviral activity and CD4 cell count benefit compared with two-drug regimens with these agents.

Original languageEnglish (US)
Pages (from-to)281-292
Number of pages12
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume21
Issue number4
StatePublished - Aug 1 1999
Externally publishedYes

Keywords

  • Antiretroviral therapy
  • Delavirdine mesylate
  • Nonnucleoside reverse transcriptase inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Fingerprint Dive into the research topics of 'Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm<sup>3</sup> (ACTG 261)'. Together they form a unique fingerprint.

  • Cite this